Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms
- 1 May 2004
- journal article
- Published by Elsevier in Analytical Biochemistry
- Vol. 328 (2) , 131-138
- https://doi.org/10.1016/j.ab.2003.12.034
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Bcl-xL antisense treatment sensitizes Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatinOral Oncology, 2002
- Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic AgentsJournal of Biological Chemistry, 2002
- Application of Micro Arrayed Compound Screening (μARCS) to Identify Inhibitors of Caspase-3SLAS Discovery, 2002
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001
- NMR Studies of the Anti-Apoptotic Protein Bcl-xL in MicellesBiochemistry, 2000
- Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studiesProtein Science, 2000
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of ApoptosisScience, 1997
- Bcl-xL forms an ion channel in synthetic lipid membranesNature, 1997
- Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell deathCell, 1995